Hepatitis D, Chronic Clinical Trial
Official title:
A Phase 2 Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection (LIMT)
To evaluate safety and tolerability of lambda over a 48-week treatment period in HDV patients.
Lambda is the pegylated form of interferon lambda-1a (IFN-λ), a conjugate of recombinant human interleukin 29 (rIL-29) and a linear polyethylene glycol (PEG) chain. IFN-λ and interferon alpha (IFN-α) share the common interferon (IFN)-stimulated gene induction pathway that leads to broad-spectrum antiviral activities. Since IFN-α has demonstrated anti-hepatitis delta virus (HDV) activity in patients with chronic hepatitis delta (CHD), it is postulated that pegylated IFN-λ could also induce HDV ribonucleic acid (RNA) decline in patients with CHD. Based on IFN-λ's more limited receptor distribution and previous data from studies involving treatment with IFN-λ in patients with hepatitis B virus (HBV) or hepatitis C virus (HCV), it is postulated that Lambda treatment could be associated with fewer adverse effects than IFN-α treatment. This Phase II study is designed as randomized, open-label study of Lambda 120 or 180 μg subcutaneous (SC) injection weekly for 48 weeks in patients with chronic HDV infection, and the primary objectives of the study are as follows: - To evaluate the safety and tolerability of treatment with 2 dose levels of Lambda over a 48-week treatment period. - To evaluate the effect of treatment with 2 different doses of Lambda on HDV RNA levels. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05461170 -
SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.
|
Phase 2 | |
| Active, not recruiting |
NCT04535544 -
A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus
|
Phase 2 | |
| Completed |
NCT02732639 -
A Study of Pegylated Interferon (PEG-IFN) Alfa-2a (Pegasys) in Participants With Chronic Hepatitis D (CHD)
|
Phase 3 | |
| Completed |
NCT02731131 -
A Study of Peginterferon Alfa-2a With or Without Ribavirin in Participants With Chronic Hepatitis D (CHD)
|
Phase 2 | |
| Active, not recruiting |
NCT05229991 -
Once Daily Dosing of Lonafarnib Co-administered With Ritonavir for Treatment of Chronic Hepatitis D Virus Infection
|
Phase 3 | |
| Terminated |
NCT01861444 -
An Observational Study on the Prevalence of Chronic Hepatitis D in Romania and the Efficacy of Treatment With Pegasys (Peginterferon Alfa-2a)
|
N/A | |
| Active, not recruiting |
NCT03105310 -
Pegylated Interferon Alone or in Combination With Ezetimibe for Patients With Chronic Hepatitis D
|
Phase 2 | |
| Recruiting |
NCT04166266 -
Observatory of Efficacy and Safety of Bulevirtide in Patients With Chronic HBV/HDV Co-infection
|
||
| Completed |
NCT01088659 -
A Study of Pegasys (Peginterferon Alfa 2a) Alone or in Combination With Tenofovir in Patients With Chronic Hepatitis D.
|
Phase 3 | |
| Completed |
NCT00686790 -
Efficacy of Peginterferon Alfa-2b in Previously Untreated Subjects With Chronic Hepatitis B and D Co-infection (Study P04603)
|
Phase 3 | |
| Completed |
NCT02876419 -
A Long Term Follow-up Study of Patients From the REP 301 Protocol
|